AMA allocates a new Category 1 CPT code for High Intensity Focused Ultrasound (HIFU)   Definitive CPT code will cover the transrectal ablation of malignant prostate tissue with HIFU including ultrasound guidance LYON, France , June 10, 2019 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”) , the global

EDAP Reports 2019 First Quarter Results HIFU revenue growth of 58.6% year-over-year Profitable for second consecutive quarter Total Q1 revenues of EUR 10.1 million ; strongest Q1 to date Improved Q1 gross profit margin by 4.2 percentage points vs prior year LYON, France , May 15, 2019 -- EDAP TMS

Company to host conference call and webcast on Thursday, May 16 , at 8:30 am EDT LYON, France , May 2, 2019  -  EDAP TMS SA  (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the first quarter ended March 31, 2019 after the

EDAP to Provide Live Demonstrations and Host Q&A with Interested Parties at Booth #2211 LYON , France, April 29, 2019 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it will demonstrate the capabilities of its range of minimally-invasive therapeutic

Reports record revenues for the fifth consecutive year Record fiscal year 2018 revenues of €39.2 million Q4 2018 HIFU net sales increased 79% year-over-year Profitable and cash flow positive during the fourth quarter of 2018 Completed first U.S. sale of Focal One at the end of 2018 Ended the year

Focal One's precision means qualifying prostate cancer patients can forego prostate removal surgery and avoid life-altering side effects including incontinence and impotence LYON, France - April 1, 2019 - EDAP TMS SA (Nasdaq: EDAP) , the global leader in therapeutic ultrasound, today announced that

Company to host conference call and webcast on Tuesday, April 2 at 8:30am EDT LYON , France, March 21, 2019  -  EDAP TMS SA  (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the fourth quarter and year ended December 31,

    Houston Methodist's Upgrade from Ablatherm to Focal One Reinforces EDAP's Position as a Leading HIFU Innovator LYON, France , March 4, 2019 -- EDAP TMS SA (Nasdaq: EDAP) -- Houston Methodist Hospital , one of the first hospitals in the U.S. to offer Ablatherm® Robotic High Intensity Focused

UC I Health , one of the three US medical centers to acquire EDAP's Focal One device, is a recognized leader in prostate cancer diagnosis and treatment utilizing robot-assisted and minimally invasive technologies LYON, France , February 5 , 2019 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the

Maimonides Medical Center to Become the First Hospital on the East Coast of the US to Acquire Focal One Technology and Offer the World's Most Advanced HIFU Prostate Treatment LYON, France - January 18, 2019 - EDAP TMS SA (Nasdaq: EDAP) today announced that Brooklyn, New York's Maimonides Medical